Johnson & Johnson

Single-digit price-hike pledge? J&J has that covered already, company report says

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's

What's wrong with Sanofi's dealmaking approach? To hear Actelion tell it, plenty

EMA examines key Actelion med Uptravi following 5 patient deaths in France

Diabetes drugs pop on January's TV ad spending list, but AbbVie's Humira stays at the top

Can Xarelto's trial win in artery disease help J&J keep rival Eliquis at bay?

J&J CEO is advocating that Trump and Republicans maintain some ACA provisions

J&J finally grabs Actelion's marketed meds for $30B, with R&D spinoff to come

Key J&J meds disappoint in Q4, triggering a top-line miss